Owkin signs AI drug discovery deal with Boehringer for cancer, immunology

Sept 2 : AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases.The deal adds Boehringer to a growing list of drugmak

Raccontata dachannelnewsasia.com